News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Isis Pharmaceuticals, Inc. (ISIS) Could Get $2 Billion Gain From Heart Attack Trials



6/20/2014 7:09:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Isis Pharmaceuticals Inc. (ISIS), a maker of gene therapy treatments, may seek to expand use of an experimental drug targeting triglycerides to fight heart disease, a move an analyst says could add $2 billion in sales.

The drug targets the APOC3 gene and is now aimed solely at a rare disease that’s linked to diabetes and pancreatitis and affects about 5,000 people. Two studies this week, however, have also tied the gene to lower risk of heart disease, an illness that kills 600,000 people yearly, a much larger target.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES